Artelo Biosciences reports Q1 EPS (72c) vs (78c) last year

“All of our lead programs are expected to achieve important milestones over the next 12 months,” said Gregory D. Gorgas, President and CEO of Artelo Biosciences (ARTL). “With additional published preclinical studies demonstrating the utility of FABP5 in oncology and dermatology, we are eager to share the results of our Phase 1 safety trial of ART26.12 in the next few weeks. ART26.12 represents the first product candidate to enter the clinic from our extensive library of selective FABP inhibitors, each with potential tailored use across multiple therapeutic areas, including cancer and inflammatory diseases.”